Mercury Laboratories Share Price Today | Stock Price & Mercury Laboratories Share Screener
As of October 5, 2026, the live Mercury Laboratories share price (BSE: MERCURYLAB) is ₹780.00, up 4.28% from the previous close, with shares trading between ₹780.00 and ₹785.00 in today's trading session, and a 52-week range of ₹700.00–₹904.00. Check MERCURYLAB 52-week performance for the annual price range and momentum. Use the Mercury Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Mercury Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹76 and net income of ₹4, with EBITDA of ₹9, an operating margin of 10.0% and a profit margin of 5.3%.
Mercury Laboratories Share Price Chart
Track the current stock price of Mercury Laboratories with an interactive chart. Analyse MERCURYLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Mercury Laboratories stock quote in one place.
The quote of ₹780.00 sits between the 52-week low of ₹700.00 and the 52-week high of ₹904.00, and the latest session moved 4.28% from the previous close.
Mercury Laboratories Company Profile - Fundamental Screener
Screen Mercury Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MERCURYLAB shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE947G01011.
Company Details
Classification
Identifiers and Leadership
Mercury Laboratories Balance Sheet Screener
Screen MERCURYLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹79, up from ₹74 in 2025.
Latest statistics put total assets at ₹79 and shareholder funds at ₹58, with a leverage ratio of 0.12.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 79 | 74 | 68 | 64 | 62 | 65 | 56 | 57 | 52 | 51 |
| Current Assets | 45 | 39 | 40 | 40 | 35 | 38 | 32 | 32 | 30 | 32 |
| Fixed Assets | 24 | 25 | 24 | 24 | 26 | 26 | 24 | 24 | 21 | 18 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 9 | 6 | 5 | 4 | 6 | 10 | 9 | 11 | 12 | 10 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 58 | 54 | 51 | 46 | 40 | 37 | 32 | 29 | 26 | 25 |
| Share Capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves & Surplus | 57 | 52 | 50 | 44 | 39 | 36 | 31 | 28 | 25 | 23 |
Mercury Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Mercury Laboratories income statement and profit fundamentals. Analyze MERCURYLAB quarterly results. Mercury Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹76 and net profit was ₹4, equal to earnings per unit of ₹34.70, at an operating margin of 10%.
In that period expenses were ₹66, interest cost ₹0 and tax ₹1. The next period listed, 2026-March, shows revenue of ₹78 and net profit of ₹5.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 76 | 78 | 76 | 77 | 77 | 59 | 70 | 58 | 57 | 52 | 48 | 48 | 42 |
| Expenses | 66 | 67 | 68 | 67 | 67 | 51 | 59 | 51 | 50 | 48 | 41 | 41 | 35 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 9 | 11 | 8 | 10 | 10 | 8 | 11 | 7 | 7 | 5 | 7 | 7 | 7 |
| Operating Profit % | 10.00% | 12.00% | 9.00% | 12.00% | 11.00% | 12.00% | 14.00% | 11.00% | 10.00% | 9.00% | 14.00% | 14.00% | 14.00% |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Interest | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 5 | 7 | 5 | 7 | 7 | 5 | 8 | 4 | 4 | 3 | 5 | 5 | 5 |
| Tax | 1 | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 0 | 2 | 1 | 1 |
| Net Profit | 4 | 5 | 3 | 6 | 6 | 4 | 5 | 3 | 3 | 2 | 3 | 4 | 3 |
| EPS | 34.70 | 40.28 | 26.21 | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 | 23.63 | 16.78 | 22.53 | 32.69 | 27.61 |
Mercury Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen MERCURYLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹4, and net cash flow was an inflow of ₹4.
Over the same period, investing activities used ₹3 and financing activities provided ₹3.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 4 | 5 | 8 | 3 | 5 | 8 | 6 | 5 | 5 | 2 |
| Investing Activities | -3 | -9 | -6 | -1 | -2 | -5 | -1 | -5 | -4 | -2 |
Financing and Net Cash | ||||||||||
| Financing Activities | 3 | -2 | -1 | -1 | -1 | -1 | -3 | -3 | 1 | 0 |
| Net Cash Flow | 4 | -6 | 1 | 0 | 2 | 2 | 1 | -2 | 2 | 0 |
Mercury Laboratories Shareholding Pattern Screener
See Mercury Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Mercury Laboratories promoter holding and ownership changes for MERCURYLAB on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 73.66%, foreign institutions 0.00%, domestic institutions 0.00% and the public 16.58%, spread across 1,316 shareholders.
The shareholder count was 1,316 in 2026-Mar, compared with 1,328 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% | 73.66% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.58% | 16.58% | 16.66% | 16.66% | 16.71% | 16.59% | 16.86% | 16.86% |
| Other Holding | 9.77% | 9.76% | 9.68% | 9.68% | 9.63% | 9.76% | 9.48% | 9.48% |
| Shareholder Count | 1,316 | 1,328 | 1,397 | 1,384 | 1,365 | 1,321 | 1,214 | 1,259 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Mercury Laboratories. Mercury Laboratories dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹3.50 per unit for 2026-March, a yield of 0.45%, compared with ₹3.50 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹3.50, ₹3.50 and ₹3.50 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹3.50 | 0.45% |
| 2025-March | ₹3.50 | 0.50% |
| 2024-March | ₹3.50 | 0.43% |
| 2023-March | ₹3.50 | 0.42% |
| 2022-March | ₹3.50 | 0.63% |
| 2021-March | ₹3.50 | 0.72% |
| 2020-March | ₹2.00 | 0.31% |
| 2019-March | ₹1.50 | 0.53% |
| 2018-March | ₹1.50 | 0.44% |
| 2017-March | ₹1.50 | 0.38% |
Mercury Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Mercury Laboratories stock. Check MERCURYLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Mercury Laboratories Market Events Screener - Corporate Actions
Get Mercury Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Mercury Laboratories stock events that may affect MERCURYLAB share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 28, 2026, with a record date of September 28, 2026.
It is followed by Dividend dated September 21, 2026 and Quarterly Result Announcement dated July 25, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-28 | 2026-09-28 | Annual General Meeting | NA | 8.60% |
| 2026-09-21 | 2026-09-21 | Dividend | ₹ 3.50 /share | 1.69% |
| 2026-07-25 | 2026-07-25 | Quarterly Result Announcement | NA | 4.91% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 3.61% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 2.06% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 2.38% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -6.45% |
| 2025-08-13 | 2025-08-13 | Annual General Meeting | NA | -4.77% |
| 2025-08-06 | 2025-08-06 | Dividend | ₹ 3.50 /share | -0.90% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -1.75% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -4.38% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.88% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -1.49% |
| 2024-09-20 | 2024-09-21 | Dividend | ₹ 3.50 /share | 19.51% |
| 2023-09-20 | 2023-09-21 | Dividend | ₹ 3.50 /share | 25.90% |
Mercury Laboratories Competitors Screener - Peer Stocks Comparison
Screen MERCURYLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 444,813 | 36.44 | 61,674 | 12.69% | 11,565 | 40.74 |
| Divis Laboratories | 253,841 | 86.51 | 11,067 | 13.95% | 2,568 | 63.87 |
| Torrent Pharmaceuticals | 185,791 | 85.91 | 13,886 | 20.34% | 2,138 | 46.50 |
| Zydus Life Science | 122,519 | 26.32 | 27,658 | 17.64% | 5,026 | 66.57 |
| Cipla | 112,291 | 33.44 | 29,045 | 2.24% | 3,870 | 45.42 |
| Laurus Labs | 109,089 | 99.70 | 6,868 | 22.01% | 890 | 64.04 |
| Dr Reddys Laboratories | 103,766 | 32.05 | 35,059 | 3.90% | 4,158 | 63.11 |
| Mankind Pharma | 100,639 | 48.73 | 14,636 | 14.85% | 1,938 | 55.24 |
| Aurobindo Pharma | 97,642 | 26.36 | 34,145 | 5.56% | 3,503 | 54.66 |
| Lupin | 94,921 | 16.99 | 29,039 | 26.75% | 5,356 | 35.30 |
Mercury Laboratories Company Announcements - News & Reports Screener
Screen MERCURYLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated October 3, 2026 and September 3, 2026.
| Date | Update | Actions |
|---|---|---|
| Shareholder Meeting / Postal Ballot-Outcome of AGM | - | |
| 2026-10-03 | Closure of Trading Window | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-01 | Reg. 34 (1) Annual Report. | - |
| 2026-09-01 | Submission Of Notice Of The 45Th Annual General Meeting Of The Company | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-21 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-20 | Communication To Shareholders - Intimation On Tax Deduction On Dividend | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-25 | Unaudited Financial Results For The Quarter Ended On June 30 2026 | - |
| 2026-07-25 | Board Meeting Outcome for Outcome Of The Board Meeting Held On July 25 2026 | - |
| 2026-07-16 | Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended On June 30 2026. | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-04 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-01 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-06-25 | Closure of Trading Window | - |
| 2026-06-11 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-05-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Corrigendum To Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31 2026 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹780.00, within a 52-week range of ₹700.00 to ₹904.00. The P/E ratio is 22.59 and the P/B ratio is 1.62, with earnings per unit of ₹40.28. Market capitalisation stands at ₹94.10 Cr and the dividend yield is 0.45%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.